Every 10-Q that ALX Oncology Holdings Inc. (ALXO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALXO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALXO filings page.
ALX Oncology Holdings Inc. reported unaudited results for the quarter ended June 30, 2026, as it continues to develop its evorpacept and ALX2004 oncology programs. The company has not realized product revenues from its planned principal operations and remains focused on clinical trials in HER2‑positive and EGFR‑expressing cancers.
For the three months ended June 30, 2026, net loss was $17,971 thousand, or $(0.13) per share, compared with $25,949 thousand, or $(0.49) per share, a year earlier. Total operating expenses were $18,033 thousand, driven mainly by research and development of $13,138 thousand and general and administrative expense of $5,133 thousand, and included a $238 thousand lease termination gain versus a $3,175 thousand impairment charge in 2025.
Liquidity increased significantly. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026, compared with $48.3 million at December 31, 2025, reflecting a February 2026 registered equity offering that generated approximately $140.4 million in net proceeds and a new $10.0 million HSBC term loan that refinanced prior debt. Net cash used in operating activities was $34,705 thousand for the first half of 2026, and management states existing capital resources are expected to fund projected operating requirements for at least the next twelve months after the financial statements are issued.
ALX Oncology Holdings Inc. reported a narrower net loss of $17.9 million for the three months ended March 31, 2026, compared with $30.8 million a year earlier, as it reduced spending while advancing its cancer pipeline.
Research and development expenses fell to $13.6 million and general and administrative costs to $5.4 million, largely due to a 2025 workforce reduction and pipeline prioritization. The company remains a clinical‑stage biotech focused on its CD47 blocker evorpacept and EGFR‑targeted ADC ALX2004, with multiple ongoing and planned trials in solid tumors and blood cancers.
ALX Oncology strengthened its balance sheet through a February 2026 equity financing, ending the quarter with $169.1 million in cash, cash equivalents and investments and an accumulated deficit of $740.7 million. Management expects these resources to fund operations for at least 12 months while it continues development and regulatory activities.
ALX Oncology (ALXO) reported Q3 2025 results highlighted by lower operating expenses and a smaller loss. Operating expenses were $22.5 million versus $32.6 million a year ago, driven by research and development of $17.4 million and general and administrative of $5.1 million. Net loss was $22.1 million, or $0.41 per share, compared with $30.7 million, or $0.58 per share, in Q3 2024.
Liquidity and balance sheet: Cash, cash equivalents and investments totaled $66.5 million as of September 30, 2025. Net cash used in operating activities was $65.2 million for the nine-month period. The company recorded a $3.2 million impairment in 2025 related to a planned sublease of a Palo Alto facility. Term loan balances were $4.3 million current and $5.8 million non-current. Management believes existing capital resources will fund operations for at least twelve months after the statements are issued.
Pipeline update: An exploratory analysis from the ASPEN‑06 gastric/GEJ study identified CD47 overexpression as a predictive biomarker in patients with retained HER2 expression, with reported outcomes including 65.0% ORR vs 26.1%, 25.5 vs 8.4 months median DOR, and improvements in PFS and OS for Evo‑TRP versus TRP.
ALX Oncology Holdings reported unaudited Q2 2025 results showing total assets of $95.3 million and total stockholders' equity of $64.4 million. Cash and cash equivalents were $19.3 million with short-term investments of $60.0 million and long-term investments of $4.2 million, for a total fair-value investment balance of $81.8 million. The company recorded a net loss of $25.9 million for the three months ended June 30, 2025 and $56.7 million for the six months, and had an accumulated deficit of $677.8 million.
Operationally, R&D expense was $18.0 million in the quarter (down 48% year-over-year), driven by lower clinical and preclinical spend and reduced stock-based compensation. The company recognized a $3.2 million impairment charge related to a to-be-sublet Palo Alto property. Clinical highlights include ASPEN-06 Phase 2 signals: ITT ORR of 41.3% versus 26.6% TRP control and stronger benefit in CD47-high patients (e.g., ORR 65% in confirmed HER2+/CD47-high subgroup). The IND for ALX2004 was cleared in April 2025. The company received a Nasdaq minimum bid price notice on April 23, 2025 with a compliance period through October 20, 2025, and states existing capital resources are sufficient for at least the next 12 months.